Current Anticholinergic Medication Use And Cognitive Impairment In The Older Population: The Medical Research Council Cognitive Function and Ageing Study

Department of Psychiatry, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK.
Journal of the American Geriatrics Society (Impact Factor: 4.57). 06/2011; 59(8):1477-83. DOI: 10.1111/jgs.2011.59.issue-8
Source: PubMed


To determine whether the use of medications with possible and definite anticholinergic activity increases the risk of cognitive impairment and mortality in older people and whether risk is cumulative.
A 2-year longitudinal study of participants enrolled in the Medical Research Council Cognitive Function and Ageing Study between 1991 and 1993.
Community-dwelling and institutionalized participants.
Thirteen thousand four participants aged 65 and older.
Baseline use of possible or definite anticholinergics determined according to the Anticholinergic Cognitive Burden Scale and cognition determined using the Mini-Mental State Examination (MMSE). The main outcome measure was decline in the MMSE score at 2 years.
At baseline, 47% of the population used a medication with possible anticholinergic properties, and 4% used a drug with definite anticholinergic properties. After adjusting for age, sex, educational level, social class, number of nonanticholinergic medications, number of comorbid health conditions, and cognitive performance at baseline, use of medication with definite anticholinergic effects was associated with a 0.33-point greater decline in MMSE score (95% confidence interval (CI)=0.03-0.64, P=.03) than not taking anticholinergics, whereas the use of possible anticholinergics at baseline was not associated with further decline (0.02, 95% CI=-0.14-0.11, P=.79). Two-year mortality was greater for those taking definite (OR=1.68; 95% CI=1.30-2.16; P<.001) and possible (OR=1.56; 95% CI=1.36-1.79; P<.001) anticholinergics.
The use of medications with anticholinergic activity increases the cumulative risk of cognitive impairment and mortality.

Download full-text


Available from: Kathryn Richardson, Nov 24, 2014
    • "The use of anticholinergic drugs to treat bladder dysfunction , mood, and pain is widespread in older adults, and over-the-counter medications that antagonise muscarinic receptors are also freely available. Several other drugsnotclassicallycategorisedasantimuscarinicsalso exhibit a degree of anticholinergic activity [9], with increasing evidence that greater anticholinergic burden is associated with both future cognitive decline and mortality [10]. Moreover, recent work demonstrated a greater risk of dementia, largely Alzheimer's disease (AD), with higher cumulative use of anticholinergics [11]. "

    No preview · Article · Oct 2015 · Journal of Parkinson's Disease
  • Source
    • "Investigations into anticholinergic side effects of medication sometimes prescribed to patients with hypertension and congestive HF have found that some of these therapeutic agents are associated with CogI [36]. A longitudinal study of 13,004 participants assessed the risk of CogI with use of anticholinergic medication. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prevalence studies have noted the cooccurrence of cognitive decline and depression in persons with heart failure. Cognitive impairment is associated with significant mortality and deteriorated quality of life, likely due to impairments in memory and executive function, which impact a patient's ability to understand and comply with prescribed treatment plans. This is especially true in complex diseases such as heart failure. Evidence from literature supports the possibility of a pathophysiological relationship between cognitive impairment, depression, and heart failure. Yet, very few studies have sought to investigate this relationship. This paper reviews current literature on the association between depression and cognitive impairment in persons with heart failure and explores possible mechanisms explaining this complex triad.
    Full-text · Article · Aug 2012 · Cardiology Research and Practice
  • Source
    • "A placebo might offer the theoretical advantage of an inexpensive treatment that would not cause adverse drug reactions or interactions with other medications, potentially avoiding complications of polypharmacy. The problems with polypharmacy in older patients were recently highlighted by Fox and colleagues [52]. They showed that patients taking a cocktail of drugs with anticholinergic properties had increases in cognitive impairment and mortality. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The therapeutic response to a drug treatment is a mixture of direct pharmacological action and placebo effect. Therefore, harnessing the positive aspects of the placebo effect and reducing the negative ones could potentially benefit the patient. This article is aimed at providing an overview for clinicians of the importance of contextual psychosocial variables in determining treatment response, and the specific focus is on determinants of the placebo response. A better understanding of the physiological, psychological, and social mechanisms of placebo may aid in predicting which contexts have the greatest potential for inducing positive treatment responses. We examine the evidence for the role of psychological traits, including optimism, pessimism, and the effect of patient expectations on therapeutic outcome. We discuss the importance of the patient-practitioner relationship and how this can be used to enhance the placebo effect, and we consider the ethical challenges of using placebos in clinical practice.
    Full-text · Article · Mar 2012 · Arthritis research & therapy
Show more